EHR-based annual PSA reminder and shared decision-making program across a 10-hospital system
Official title: Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Run by Washington University School of Medicine · NCT07109427 · Data updated 2026-11-12
This trial will test whether an annual electronic health record reminder that prompts shared decision-making and guideline-based referral improves PSA screening and appropriate follow-up for men at average or high risk in a large health system.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 75 Years |
| Sex | Men only |
| Enrollment | 40000 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | August 11, 2025 |
| Main results expected | August 31, 2031 |
| Study ends | August 31, 2031 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07109427 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men who receive primary care within the BJC Health System, have had at least one primary care visit in the screening year, are age 50–75 (or age 40–75 if African American or otherwise high risk), and do not have a history of prostate cancer are ideal candidates.
✕Probably not a fit
People outside the BJC Health System, women, men with a prior prostate cancer diagnosis, or men outside the specified age/risk ranges are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The program adds an annual PSA health maintenance reminder to the electronic health record with defined referral thresholds aligned to NCCN risk stratification and enhanced clinical decision support to guide clinicians. It targets men receiving primary care within a 10-hospital integrated system and uses system-level tools to reduce provider variation in screening and referral practices. The intervention emphasizes shared decision-making at the point of care and standardized referral triggers intended to prioritize clinically significant disease while limiting overdiagnosis. Outcomes include screening rates, guideline-concordant referrals, and downstream presentation stage.
Why it matters
Potential benefit: If successful, the intervention could increase guideline-concordant PSA screening and timely referral, reducing late-stage prostate cancer presentations without markedly increasing overdiagnosis.
How similar studies have gone: Previous work shows that EHR alerts and decision-support tools can increase guideline-concordant screening and shared decision-making, though effects on reducing late-stage cancer diagnosis are less consistently proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria:
* Receive care within the BJC Health System
* Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)
* Be male
* Not have a history of prostate cancer
* Meet one of the following risk criteria:
* High Risk for Prostate Cancer
* African American, between the ages of 40 and 75 (inclusive), or
* Family history of prostate, breast, ovarian, and/or pancreatic cancer, or
* Known familial germline mutation OR
* Average Risk for Prostate Cancer
* Between the ages of 50 and 75 (inclusive)
Where it's running
-
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Lannis Hall, M.D., MPH — Washington University School of Medicine
- Study coordinator: Lannis Hall, M.D., MPH
- Email: lannishall@wustl.edu
- Phone: 636-916-9947
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-count SPECT imaging to guide Radium-223 treatment for men with bone-metastatic prostate cancer
This study tests whether low-count quantitative SPECT can help tailor Radium-223 therapy for men with prostate cancer that has spread to the bones.
-
Using AI to help find prostate cancer on MRI
This study tests whether an AI software can help doctors find suspicious lesions on prostate MRI in men aged 55–80 who are having a pre-biopsy MRI and planned prostate biopsy.
-
Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve
This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.